
    
      The purpose of the escalation part of the trial is to determine the recommended phase 2 dose
      (RP2D) and the maximum tolerated dose (if reached) as well as establish the safety profile of
      epcoritamab in patients with R/R CLL.

      In the expansion part additional patients will be treated with epcoritamab at the RP2D and
      the the purpose is to assess and evaluate the preliminary efficacy, safety and tolerability
      profiles of epcoritamab at the RP2D.
    
  